Determining the extent of quality health care for hospitalized patients with cirrhosis

Hepatology

Volumn 42, Issue 2, 2005, Pages 492-494

  Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; SPIRONOLACTONE; VITAMIN K GROUP;

ASCITES; BACTERIAL INFECTION; CHILD PUGH SCORE; COHORT ANALYSIS; DISEASE COURSE; ESOPHAGUS VARICES BLEEDING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE QUALITY; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NOTE; PORTAL HYPERTENSION; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL RATE;

HEPATITIS C; HOSPITALIZATION; HUMANS; LIVER CIRRHOSIS; PATIENT READMISSION; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE;

EID: 23044444761     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20753     Document Type: Note

References (18)

1. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002; 50:1-85.
2. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. HEPATOLOGY 2002;36:227-242.
3. Wong LL, McFall P, Wong LM. The cost of dying of end-stage liver disease. Arch Intern Med 1997;157:l429-l432.
4. HCUPnet, Healthcare Cost and Utilization Project. Rockville, MD: Agency for Healthcare Research and Quality. Available at http://www.ahr-q.gov/hcupnet/
5. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001.
6. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, Havranek EP, et al. Evaluating quality of care for patients with heart failure. Circulation 2000;101:E122-E140.
7. Arroyo V, Gines A, Salo J. A European survey on the treatment of ascites in cirrhosis. J Hepatol 1994;21:667-672.
8. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999;94:2224-2229.
9. Talwalkar JA, Kamath PS. An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. Am J Med 2004;116:759-766.
10. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. HEPATOLOGY 2001;33:802-807.
11. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. HEPATOLOGY 1999;29:1655-1661.
12. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Caleras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-830.
13. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F; Spanish Collaborative Study Group On Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 2002;58:435-440.
14. Chalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003;98:653-659.
15. Sorbi D, Gostout CJ, Peura D, Johnson D, Lanza F, Foutch PG, et al. An assessment of the management of acute bleeding varices: a multicenter prospective member-based study. Am J Gastroenterol 2003;98:2424-2434.
16. Talwalkar JA. Economic impact of hospitalization for end-stage liver disease. Am J Gastroenterol 2002;97:1562.
17. Bini EJ, Weinshel EH, Generoso R, Salman L, Dahr G, Pena-Sing I, Komorowski T. Impact of gastroenterology consultation on the outcomes of patients admitted to the hospital with decompensated cirrhosis. HEPATOLOGY 2001;34:1089-1095.
18. Talwalkar JA, Kamath PS. Impact of specialist care on outcomes in end-stage liver disease. J Hepatol 2002;37:543.